Full-Time
IT Technical Analyst / Senior IT Technical Analyst
Confirmed live in the last 24 hours
Beam Therapeutics
501-1,000 employees
Develops precision genetic medicines using base editing
No salary listed
Mid, Senior
Cambridge, MA, USA
- 3+ years of successful experience in configuring and supporting Veeva Vault, preferably the Vault Quality Suite. Hands on configuration experience with Veeva Vault is required.
- 5+ years of successful IT experience in system development lifecycle (SDLC) activities (requirements, design, configuration, validation/testing, and support).
- Strong analytical and troubleshooting skills.
- Experience with eliciting business requirements and translating into technical deliverables.
- Gather and document business requirements and ensure these are translated into high quality technical solutions that meet the needs of our organization.
- Lead continuous improvement efforts for Beam’s Veeva Quality Vault. Partner closely with business stakeholders and Veeva to collect and prioritize enhancement requests and own successful delivery of configuration changes through Beam’s internal release process.
- Support validation and change management activities, including contributing to requirements documentation, test scripts, and change control documentation.
- Serve as primary operational support to resolve any system related issues.
- Support the larger IT organization by assuming other duties and responsibilities, as assigned.
- Veeva Vault Administrator Certification(s) desired.
- Experience with Computer Systems Validation (CSV).
- Experience with Quality Systems (Controlled Document Management, Training, Change Control, Deviations, etc.) preferred.
- Some Project Management experience is helpful.
Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise changes to the genetic code to correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures instead of temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and potential commercialization of their treatments after regulatory approval. Beam Therapeutics distinguishes itself from competitors by emphasizing a values-driven approach, a strong team of experts, and a commitment to rigorous scientific development. The ultimate goal of the company is to advance genetic medicine to improve the lives of patients suffering from genetic disorders.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2017
Simplify's Take
What believers are saying
- Beam raised $500 million to advance its R&D and expand its genetic medicine pipeline.
- Successful Phase 1/2 trial for BEAM-302 shows potential beyond sickle cell disease.
- Partnership with Eli Lilly highlights commercial potential and industry confidence in Beam's technology.
What critics are saying
- Increased competition from CRISPR Therapeutics could impact Beam's market share.
- New CFO appointment may lead to transitional challenges or shifts in financial strategy.
- $500 million equity offering may dilute existing shareholders' value, causing dissatisfaction.
What makes Beam Therapeutics unique
- Beam Therapeutics uses base editing, a safer alternative to traditional CRISPR methods.
- The company focuses on lifelong cures for genetic disorders, not just symptom management.
- Beam's technology targets single base changes without causing double-stranded DNA breaks.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%CAMBRIDGE, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...
Beam Therapeutics announced promising initial safety and efficacy data from its Phase 1/2 trial of BEAM-302 for treating alpha-1 antitrypsin deficiency (AATD). The trial showed BEAM-302 was well tolerated and led to dose-dependent correction of the disease-causing mutation. Beam plans to continue the trial and report further data in 2025. Additionally, Beam raised $500 million through an equity offering. BEAM stock was down 3.44% at $27.50 in premarket trading.
CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024.
CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase.
Rare Diseases – Curing The IncurableWhile not entirely solved, a lot of major deadly illnesses that have plagued humanity have become more manageable over the last century, from bacterial (antibiotics) and viral (vaccines) infections to diabetes (insulin).There is, however, a wide array of rare diseases which are still mostly incurable. Most of the time, this is because these diseases are not caused by an external threat, but by a biological dysfunction inside the very cells of the patient. This is quickly changing, thanks to progress in biosciences.On one hand, with the human genome sequenced and much more advanced analytical methods, scientists can finally understand what are the root causes of rare diseases. Even AI is now helping interpret the data and provide new insights .On the other hand, new technologies like gene editing open the possibility of fixing deficient cells or organs, restoring normal function.Rare diseases each affect less than 1 in 2,000 people, with more than 6000 different rare diseases. Despite their individual rarity, together, they affect around 4% of the population, with as many as 30 million people in just Europe .3/4 of rare diseases affect children, 72% are genetic in origin, and it takes on average 5 years for rare disease patients to get a diagnosis.CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a recently discovered tool for genetic editing. It allows for very precise and directed gene editing, and its discoverers have won the 2020 Nobel Prize .What sets CRISPR Therapeutics apart is the all-star team of founders, including Dr